An observational study in Malaria Transmission, sponsored by University Hospital Tuebingen. Completed at 2 sites in 2 countries. Open to participants aged 6 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-04.
Sponsored by University Hospital Tuebingen · Observational
Assessing the effect of neglected tropical diseases on Plasmodium falciparum transmission in an area of co endemicity.
The project is divided in three different work packages that cover the life cycle of P. falciparum :
1,184 studies on the registry are indexed under Malaria; 79 are open to participants now.
This study's enrollment of 380 is below the median of 582 across 204 observational studies indexed under Malaria.
Browse Malaria studies →University Hospital Tuebingen is the lead sponsor of 490 studies on the registry; 108 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population are subjects aged from 6 to 30 years since both adults and children have been shown to be a reservoir of P. falciparum. Participants will be recruited in two African villages located in Gabon (lambarene) and Ghana Asokwa submetropolitan area in Kumasi, Ghana. Settings in the two locations are different and represent a rural area with very high infectious pressure from helminths infection (S. haematobium and geohelminths) as well as year-round transmission of malaria in the Central African rain forest (Lambaréné) and a more densely populated area in West Africa with pronounced seasonal variation in malaria transmission and high endemicity of S. haematobium but very little other helminthiases due to well-implemented mass treatment campaigns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Asymptomatic volunteers infected with S. haematobium and living in Gabon
Other: Pre-treatment follow up · Other: S. haematobium treatment · Other: Post treatment follow up · Other: Olfactometer experiment
Volunteers not infected with S. haematobium and living in Gabon
Other: Pre-treatment follow up · Other: Post treatment follow up · Other: Olfactometer experiment
Asymptomatic volunteers infected with S. haematobium and living in Ghana
Other: Pre-treatment follow up · Other: S. haematobium treatment · Other: Post treatment follow up · Other: Olfactometer experiment
Volunteers not infected with S. haematobium and living in Ghana
Other: Pre-treatment follow up · Other: Post treatment follow up · Other: Olfactometer experiment
No active intervention; medical support provided if needed
Praziquantel-treatment for S. haematobium positive volunteers
Also known as: Praziquantel-treatment
No active intervention; medical support provided if needed.
No active intervention; medical support provided if needed.
Number of participants with Plasmodium falciparum gametocytes and/or asexual blood stages
Presence of Plasmodium falciparum gametocytes and/or asexual blood stages will be assessed by a quantitative real-time PCR assay in the blood obtained from participants. Unit of measurements for both parameters is numbers/µl.
Time frame: 15 months
Number of participants with positive serum antibodies specific to the asexual and gametocyte stages of Plasmodium falciparum.
Number of participants with serum antibodies against P. falciparum gametocyte and/or asexual blood stage antigens will be assessed.
Time frame: 15 months
Percentage of mosquitoes attracted to Schistosoma-infected participants to non-infected individuals in a wind-tunnel assay.
100 mosquitoes will be released to Schistosoma infected and non-infected participants simultaneously lying in different tents in a two-way olfactometer.
Time frame: 15 months
Proportion of Plasmodium infected Anopheles mosquitoes per individual per night
Mosquitoes will be collected by Human Landing catches and species of mosquitoes and presence of Plasmodium falciparum will be determined by morphology and PCR.
Time frame: 3 months
Plan to share: No
The record gives a start of Apr 2016, a primary completion of Oct 2019 and a completion of Oct 2020. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Tuebingen →